erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Biomarkers, Tumor
  • Breast Neoplasms
  • Gene Expression Regulation, Neoplastic
  • Receptor, ErbB-2
  • Tumor Suppressor Protein p53

abstract

  • The hypothesis that patients whose breast tumors exhibit high erbB-2 expression benefit from dose-intensive CAF should be further validated before clinical implementation. Interactions between erbB-2 expression, p53 expression, and CAF dose underscore the complexities of predictive markers where multiple interactions may confound the outcome.

publication date

  • September 16, 1998

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9747866

Additional Document Info

start page

  • 1346

end page

  • 60

volume

  • 90

number

  • 18